WO2023118961 - ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF
National phase entry:
Publication Number
WO/2023/118961
Publication Date
29.06.2023
International Application No.
PCT/IB2022/000772
International Filing Date
20.12.2022
Title **
[English]
ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF
[French]
CONJUGUÉS ANTICORPS-MÉDICAMENT COMPRENANT DES TOXINES AVEC DES GROUPES POLAIRES ET LEURS UTILISATIONS
Applicants **
INTOCELL, INC.
Inventors
PARK, Taekyo
REW, Yosup
KIM, Sunyoung
JUNG, Doohwan
SEO, Donghoon
LEE, Sangkwang
HA, Jihyeon
CHOI, Jihye
JEON, Cheolmin
JEONG, Myeonghwa
KIM, Hyewon
YANG, Eun, Hye
KIM, Ya, Gob
LEE, Chohee
LEE, Hyang, Sook
SEO, Beomseok
SONG, Jina
KIM, Sena
YOO, Jae, Do
Priority Data
63/292,101
21.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 12253 | |
| EPO | Filing, Examination, Granting | 318514 | |
| Japan | Filing, Examination, Granting | 5955 | |
| South Korea | Filing, Examination, Granting | 12061 | |
| USA | Filing, Examination, Granting | 60490 |
Total:
409,273
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure is directed toward drugs and toxins functionalized by at least one saccharide, sulfate or sulfonate; drug conjugates comprising said drugs or toxins and a cleavable linker; and targeted conjugates comprising said drugs or toxins, cleavable linkers, and targeting moieties. The present disclosure also relates to methods of treating cancers, auto- immune diseases, and inflammatory diseases using the compounds and conjugates of the disclosure.[French]
La présente invention concerne des médicaments et des toxines fonctionnalisés par au moins un saccharide, un sulfate ou un sulfonate; des conjugués médicamenteux comprenant lesdits médicaments ou toxines et un lieur clivable; et des conjugués ciblés comprenant lesdits médicaments ou toxines, des lieurs clivables et des fractions de ciblage. La présente invention concerne également des méthodes de traitement de cancers, de maladies auto-immunes et de maladies inflammatoires à l'aide des composés et des conjugués de l'invention.